No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women
Open Access
- 1 December 2004
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 13 (12) , 2282-2284
Abstract
The production of endogenous estradiol, and thus the risk of breast cancer, may be affected by functional polymorphisms in the genes coding for enzymes in the steroid biosynthesis pathway. Potentially important polymorphisms have been identified in three genes: CYP17, which encodes for a P450 enzyme that catalyzes 17α-hydroxylase and C17-20 lyase activities in the biosynthesis of androgens; CYP19, which encodes for aromatase, the enzyme involved in the conversion of androgens to estrogens; and HSD17-B1, which encodes for the 17β-hydroxysteroid oxidoreductase type 1 enzyme that reduces estrone to estradiol. Several studies have observedan association between risk for breast cancer and these polymorphisms (1). However, other studies have not found such an association, and the biological relationship of these polymorphisms with circulating estrogens has yet to be established. We assessed whether polymorphisms in CYP17, CYP19, or HSD17-B1 are associated with circulating levels of estradiol, the most biologically potent estrogen. Specifically, we examined a T to C substitution 34 bp upstream of the translation initiation site in the 5′ untranslated region of CYP17 among 634 premenopausal and 455 postmenopausal British women. Among the postmenopausal women, we also examined a [TTTA]n repeat allele beginning at bp 682 (intron 4) of CYP19, an associated TCT insertion/deletion polymorphism, a C to T substitution in the untranslated region of exon 10 of CYP19, and an A to G substitution in exon 6 of HSD17-B1 1,954 bp downstream of the first nucleotide in the translation initiation codon.Study participants included 636 premenopausal and 456 postmenopausal British women recruited to the Oxford arm of the European Prospective Investigation into Cancer and Nutrition and previously studied in a cross-sectional analysis of sex hormones and risk factors for breast cancer (2, 3). Details of the estradiol assays are described elsewhere (2). One postmenopausal and two premenopausal women were excluded from the current study due to insufficient buffy coat being available for molecular analyses.Genotyping on DNA extracted from buffy coat samples was conducted blind after the hormone assays had been completed. Eight hundred and ninety-eight samples were genotyped at the Cancer Research UK Genotyping Facility in Oxford. Blinded quality control samples (3.4%) were inserted to validate genotype identification procedures: concordance for the blinded samples was 100% for the CYP17 assay, 93.3% for the CYP19 intron 4 assay, 100% for the CYP19 exon 10 assay, and 100% for the HSD17-B1 assay. One hundred and ninety-eight samples were genotyped for the CYP17 single nucleotide polymorphism at the Biomedical Research Centre in Dundee as part of a previous unpublished study using similar methods. Genotype frequencies from the two laboratories were statistically similar: CYP17 TT, TC, and CC genotype frequencies were 40.0%, 45.9%, and 14.1%, respectively, for samples assayed in Oxford and 38.4%, 47.0%, and 14.7%, respectively, for samples assayed in Dundee (χ2 = 0.18, P = 0.9). Seven samples were genotyped for CYP17 at both laboratories and there was 100% concordance between the two sets of results.Estradiol values were logarithmically transformed to reduce the positive skewness of the distributions, and geometric mean hormone values and the corresponding95% confidence intervals are presented. ANOVA was used to evaluate the association between genotypes andestradiol concentrations. Estradiol concentrations in postmenopausal women, classified by their number of putative high-risk alleles, including single nucleotide polymorphisms in CYP17, CYP19 exon 10, and HSD17-B1 were also examined. Statistical analyses were repeated with adjustment for potential confounders including age (5-year age groups), body mass index [calculated as weight/height2 (kg/m2) and grouped <20, 20<22.5, 22.5<25, 25<27.5, ≥27.5], vigorous exercise (0, 1-2, 3-4, ≥5 hours per week), and number of days the blood sample was in the post (0-1, 2, ≥3 days; among postmenopausal women only). In the analyses of data from premenopausal women, adjustment was also made for stage of menstrual cycle (early follicular, late follicular, mid-cycle, early luteal, and late luteal defined as ≥22, 16-21, 12-15, 3-11, and 0-2 days before next menstrual period), smoking status (never, former, current), alcohol consumption (<0.50, 0.50<8.0, 8.080% power at a 0.05 significance level to detect differences of 25% in plasma concentrations between women with different genotypes. The results suggest that there is no large effect of the polymorphisms studied in CYP17, CYP19, and HSD17-B1 on endogenous estradiol concentrations; however, more data would be needed to establish whether or not there is a small effect.Keywords
This publication has 7 references indexed in Scilit:
- Association of CYP17, CYP19, CYP1B1 , and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2004
- Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) Genes: Association with Serum Sex Steroid Concentrations and Bone Mineral Density in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2004
- Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre‐menopausal womenInternational Journal of Cancer, 2002
- Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndromeGynecological Endocrinology, 2001
- CYP19 gene polymorphism in endometrial cancer patientsJournal of Cancer Research and Clinical Oncology, 2001
- A tetranucleotide repeat polymorphism inCYP19 and breast cancer riskInternational Journal of Cancer, 2000
- Oestradiol and sex hormone-binding globulin in premenopausal and post-menopausal meat-eaters, vegetarians and vegansBritish Journal of Cancer, 1999